When assessing a nulligravid patient's risk for preeclampsia, what lab test is NOT useful?

In the context of assessing a nulligravid patient's risk for preeclampsia, certain laboratory tests have been established as more relevant than others. Among the choices presented, the anticardiolipin antibody test is not typically used for preeclampsia risk assessment. Preeclampsia is primarily associated with factors such as hypertension and proteinuria during pregnancy, and the common labs assessed focus more on renal function and electrolyte balance, which can be indicated by tests like creatinine levels.

Calcium levels can also be monitored, as calcium supplementation is sometimes suggested for pregnant women at high risk for preeclampsia, although its direct role in risk assessment remains less clear. However, the anticardiolipin antibody test, which is utilized mainly for assessments related to autoimmune conditions and thrombotic disorders, does not have a proven effectiveness in predicting or managing preeclampsia risk.

Therefore, the correct response identifies that none of the listed tests effectively contribute to the risk assessment for preeclampsia, with a particular emphasis on the lack of utility of the anticardiolipin antibody in this specific context.